Study on 13-Cis Retinoic Acid for Neuroblastoma in Children
Author Information
Author(s): Kohler J A, Imeson J, Ellershaw C, Lie S O
Primary Institution: Child Health, Southampton General Hospital
Hypothesis
Does 13-Cis retinoic acid improve event-free survival in children with advanced neuroblastoma after high-dose therapy?
Conclusion
The study found that 13-Cis retinoic acid did not show any advantage in event-free survival compared to placebo.
Supporting Evidence
- The study involved 175 children with advanced neuroblastoma.
- Participants were randomly assigned to receive either the treatment or a placebo.
- The treatment was administered for up to 4 years.
- Toxicity from the treatment was mild.
Takeaway
The study tested a medicine called 13-Cis retinoic acid on kids with a serious cancer, but it didn't help them live longer without problems compared to those who didn't take it.
Methodology
Children were randomly assigned to receive either 13-Cis retinoic acid or a placebo for up to 4 years.
Limitations
The study did not demonstrate a benefit in event-free survival despite mild toxicity.
Participant Demographics
Children with Stage 3 or 4 neuroblastoma who had a good response to conventional therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website